"Loteprednol Etabonate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An androstadiene derivative corticosteroid that is used as an ANTI-ALLERGIC AGENT for the treatment of inflammatory and allergic eye conditions.
| Descriptor ID |
D000069559
|
| MeSH Number(s) |
D04.210.500.054.079.129.284
|
| Concept/Terms |
Loteprednol Etabonate- Loteprednol Etabonate
- Etabonate, Loteprednol
- CEHOAC
- Chloromethyl 17-ethoxycarbonyloxy-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylate
- 17-ethoxycarbonyloxy-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylate, Chloromethyl
- Chloromethyl 17 ethoxycarbonyloxy 11 hydroxy 3 oxoandrosta 1,4 diene 17 carboxylate
|
Below are MeSH descriptors whose meaning is more general than "Loteprednol Etabonate".
Below are MeSH descriptors whose meaning is more specific than "Loteprednol Etabonate".
This graph shows the total number of publications written about "Loteprednol Etabonate" by people in this website by year, and whether "Loteprednol Etabonate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Loteprednol Etabonate" by people in Profiles.
-
Corneal Manifestations of Miltefosine Toxicity in Acanthamoeba Keratitis. Ophthalmology. 2021 09; 128(9):1273.
-
Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%. Eye Contact Lens. 2014 Sep; 40(5):289-96.
-
A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004 Sep; 138(3):444-57.